Viking Therapeutics Reports New Data from VK2735 Obesity …

SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel …

CouponFollow Extension

8%
OFF

Viking Oral Obesity Med Posts 6.8% Weight Loss For Highest Dose

6 days from now

Nov 4, 2024 · The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who …

fiercebiotech.com

2%
OFF

Viking Therapeutics Surges After Presenting ‘promising’ Obesity …

6 days from now

Nov 4, 2024 · Patients taking 100-miligram doses of Viking’s VK2735 lost 8.2% of their body weight after 28 days, or 6.8% more than those taking a placebo, and no patients taking the …

businessinsider.com

$109.00
OFF

Viking Therapeutics Stock 'well-positioned' In Obesity/T2D Market, …

6 days from now

1 day ago · On Friday, B.Riley initiated coverage on Viking Therapeutics (NASDAQ:VKTX) stock with a Buy rating and a price target of $109.00. The firm's confidence in Viking's lead program, …

investing.com

$125
OFF

Behind The $125 Billion GLP-1 Obesity Drug Boom: Four Key …

6 days from now

2 days ago · With the emergence of GLP-1 RA therapies the obesity drug market has taken off and ... Viking Therapeutics presented promising data from a mid-stage trial of its VK2735 …

pharmaboardroom.com

FAQs about Viking Therapeutics Reports New Data from VK2735 Obesity … Coupon?

Does Viking Therapeutics 'promising' early results for an obesity pill?

Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental obesity pill, with increased weight loss at higher doses, IBD’s Ed Carson reports. ...

What is Viking Therapeutics VK5211?

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company’s clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. ...

Why did Viking choose vk2735?

Viking selected VK2735 from a series of internally developed dual GLP-1/GIP receptor agonists evaluated as part of a program focused on the development of best-in-class therapies for metabolic diseases. ...

Could Viking Therapeutics' oral obesity drug be better than wegovy & zepbound?

Michael M. Santiago via Getty Images New results from a small study of Viking Therapeutics’ oral obesity drug raised expectations among Wall Street analysts that the experimental tablet could prove superior among the growing ranks of would-be competitors to the popular weight loss treatments Wegovy and Zepbound. ...

Could vk2735 be a 'long-term disruptive potential'?

Michail_Petrov-96/iStock via Getty Images B Riley has initiated Viking Therapeutics at buy saying that the company lead obesity treatment, VK2735, could have "long-term disruptive potential." The investment bank has a $109 price target (~111% upside based on Nov. 21 close). ...

Is vk2735 a mad clinical trial?

In a presentation at ObesityWeek 2024, the annual meeting of the Obesity Society, the company presented updated data from the previously reported Phase 1 multiple ascending dose or MAD clinical trial of an oral tablet formulation of VK2735 dosed daily for 28 days, including results for the study's 60 mg, 80 mg, and 100 mg daily treatment cohorts. ...